Research Profiles
WAMM
An ALLG Window study of Acalabrutinib plus Rituximab followed by R-DHAOx + ASCT in fit Mantle Cell Lymphoma
December 20, 2021
Menu
Thank you for your interest in what is currently happening in the Oncology/Haematology Department, we are working on showcasing the wonderful work across the Mackay Hospital and Health Service. If you would like to get in touch with us, please contact the MIRI team via email MIRI@health.qld.gov.au or 07 4885 6743.
An ALLG Window study of Acalabrutinib plus Rituximab followed by R-DHAOx + ASCT in fit Mantle Cell Lymphoma
Background Protocol I3Y-MC-JPCF(d) A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients